Objective-Myogenic vasoconstriction is mediated by vascular smooth muscle cells of resistance arteries sensing mechanical stretch. Angiotensin II AT 1 receptors and in particular AT 1B Rs in murine vascular smooth muscle cells have been characterized as mechanosensors that cannot fully account for myogenic vasoconstriction observed. Therefore, we aimed at uncovering novel vascular mechanosensors by expression profiling and functional characterization of candidate proteins. Approach and Results-Analyzing myogenic tone of isolated murine mesenteric arteries of AT 1A and AT 1B receptor double gene-deficient (AT 1A/1B −/− ) mice ex vivo, we observed a decreased myogenic tone at high intraluminal pressures and an unexpected hyper-reactivity at low intraluminal pressures because of upregulation of cysteinyl leukotriene 1 receptors (CysLT 1 Rs). Pharmacological blockade of CysLT 1 Rs with pranlukast significantly reduced myogenic tone not only in AT 1A/1B −/− but also in wild-type arteries. In wild-type arteries, additional blockade of angiotensin II AT 1 receptors with candesartan resulted in an additive reduction of myogenic tone. Furthermore, calcium imaging experiments were performed with fura-2-loaded human embryonic kidney 293 cells overexpressing CysLT 1 Rs and with isolated mesenteric vascular smooth muscle cells. Hypo-osmotically induced membrane stretch provoked calcium transients that were significantly reduced by pranlukast. Incubations of isolated mesenteric vascular smooth muscle cells with the 5-lipoxygenase inhibitor zileuton had no effect. Furthermore, the G q/11 -protein inhibitor YM 254890 profoundly reduced myogenic tone to the same extent as induced by the application of pranlukast plus candesartan. Conclusions-Here, we identify a novel, hitherto unappreciated role of CysLT 1 Rs in vascular regulation. We identified CysLT 1 Rs as novel mechanosensors in the vasculature involved in myogenic vasoconstriction. Moreover, our findings suggest that myogenic tone is determined by AT 1 and CysLT 1 receptors acting together as mechanosensors via G q/11 -protein activation. (Arterioscler Thromb Vasc Biol. 2015;35:121-126.
C ysteinyl leukotriene 1 receptors (CysLT 1 Rs) are known to mediate the contraction of bronchial smooth muscle. However, a potential role of these receptors in the cardiovascular system has still remained elusive. Myogenic vasoconstriction or Bayliss effect 1,2 is essential for the maintenance of vascular tone, peripheral vascular resistance, and organ perfusion. 3 Vascular smooth muscle cells (VSMCs) but not endothelial cells 4 are considered sensors for mechanical stress inducing myogenic vasoconstriction. Several proteins, such as integrins, ion channels, or membrane-associated enzymes, are discussed as mechanosensors. Recently, angiotensin II AT 1 receptors (AT 1 Rs) emerged as mechanosensors in VSMCs mediating myogenic tone and in cardiac myocytes inducing cardiac hypertrophy independent of agonist. [5] [6] [7] [8] [9] Numerous other G-protein-coupled receptors, such as the bradykinin B 2 , the endothelin ET A , the parathyroid hormone type 1, the histamine H 1 , the muscarinic M 5 , and the formyl peptide 1, are discussed as mechanosensors. 10 For some of these receptors, physiological roles emerged, for example, as sensors of fluid shear stress in endothelial cells, for retraction of pseudopods in neutrophils or for bone growth. Altogether, there is a growing evidence supporting inherent mechanosensitivity of G-protein-coupled receptors. CysLT 1 Rs are well known as constrictor receptors in bronchial smooth muscle. Any contribution of these receptors to myogenic vasoconstriction, however, is not known to date.
In contrast to humans, rodents express 2 isoforms of the AT 1 receptor: AT 1A and AT 1B . Investigating both murine AT 1 R isoforms, we recently found that mechanosensitive AT 1B but not AT 1A receptors are key elements for mechanosensation in VSMC mediating myogenic tone. 5 However, myogenic tone was not completely lost in AT 1B gene-deficient arteries or after blockade of AT 1 Rs with candesartan or losartan, suggesting that other signaling pathways might participate in myogenic tone. The aim of this study was to analyze the total effect of AT 1A and AT 1B receptors on myogenic tone by investigating AT 1A/1B double gene-deficient (AT 1A/1B −/− ) mice and to discover novel candidate mechanosensors in the vasculature.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CysLT 1 Rs Together With AT 1 Rs Mediate Myogenic Vasoconstriction via G q/11 -Proteins
To analyze myogenic tone of AT 1A/1B −/− mice ex vivo, we performed pressure myography of isolated murine mesenteric arteries (IMMAs) from AT 1A/1B −/− and wild-type (WT) mice. Unexpectedly, AT 1A/1B −/− arteries were hyper-reactive with significantly increased myogenic vasoconstriction at a premyogenic pressure range from 20 to 70 mm Hg ( Figure 1A ). Only at higher pressures >100 mm Hg, myogenic tone was significantly reduced as expected. Figure 1B shows exemplary vessel diameter time courses at incremental pressure levels. Because vascular hyper-reactivity might be caused by compensatory upregulation of other proteins, gene expression profiling was performed showing that among all G-proteincoupled receptors, only CysLT 1 Rs were significantly enriched in AT 1A/1B −/− IMMAs as confirmed by quantitative reverse-transcriptase-polymerase chain reaction ( Figure 1C ). Therefore, we pursued a pharmacological approach and applied pranlukast, a selective CysLT 1 R antagonist, at maximally inhibitory concentrations. Administration of 50 nmol/L pranlukast significantly reduced myogenic tone in the pressure range ≤90 mm Hg. At higher pressure levels, myogenic tone was reduced similar to untreated AT 1A/1B −/− IMMAs ( Figure 1A and 1D), suggesting that the hyper-reactivity at low pressure levels is mediated by CysLT 1 Rs, whereas the decrease of myogenic responsiveness at higher pressures reflects the loss of AT 1 Rs. Figure 1D shows the summary of changes of myogenic tone at different pressure ranges. Of note, candesartan did not reduce myogenic tone of AT 1A/1B −/− IMMAs (data not shown), ruling out side effects of candesartan on vascular tone. Next, we applied pranlukast to WT arteries to determine the physiological effect of CysLT 1 Rs on myogenic vasoconstriction. Interestingly, pranlukast also significantly reduced myogenic tone of WT IMMAs over a wide pressure range ( Figure 1E and 1F), suggesting that CysLT 1 Rs are generally involved in myogenic vasoconstriction. Moreover, application of montelukast caused a significant reduction of myogenic tone, which was concentration dependent ( Figure 1G and 1H). Interestingly, although 50 nmol/L montelukast was ineffective, 100 nmol/L montelukast caused the strongest reduction of myogenic tone in the middle pressure range of 70 to 90 mm Hg in contrast to 200 nmol/L montelukast additionally suppressing myogenic tone at high intraluminal pressures >100 mm Hg. These findings suggest that mechanically activated CysLT 1 Rs are particularly sensitive to selective antagonists at moderate intraluminal pressures. Furthermore, pranlukast-induced reductions of myogenic tone in WT arteries were similar to candesartan-induced reductions ( Figure 1I and 1J). Moreover, simultaneous blockade of CysLT 1 Rs and AT 1 Rs resulted in an even more pronounced reduction of myogenic tone than that induced by either drug alone ( Figure 1I and 1J). The additive effect of the blockers suggests an important role of both receptors for myogenic vasoconstriction and supports the notion that both receptors act together as mechanosensors.
To analyze whether mechanical receptor activation during myogenic vasoconstriction was subject to the same signaling pathway as initiated by agonist stimulation, we applied YM 254890, a potent and selective G q/11 -protein inhibitor. 11 Interestingly, YM 254890 suppressed myogenic tone to a similar extent as observed after simultaneous blockade of AT 1 Rs and CysLT 1 Rs ( Figure 1K and 1L) amounting to a relative reduction of myogenic tone of >63%. These findings indicate that myogenic vasoconstriction is mainly mediated by AT 1 Rs and CysLT 1 Rs signaling through the G q/11 -protein pathway. To analyze whether mechanically induced CysLT 1 Rs activation during myogenic vasoconstriction is agonist independent, the 5-lipoxygenase inhibitor zileuton was incubated for ≥30 minutes to prevent leukotriene production. Interestingly, zileuton slightly but significantly reduced myogenic tone only at high pressures ( Figure 1M and 1N ), suggesting an involvement of endogenously produced leukotrienes in myogenic vasoconstriction. Because endothelial cells can produce leukotrienes, 12, 13 we next analyzed whether the endothelium might be responsible for zileuton-induced vasorelaxation. For this, arteries were de-endothelialized by intraluminal administration of an air bubble. Interestingly, de-endothelialized, zileuton-treated vessels showed normal myogenic vasoconstriction ( Figure 1M and 1N ), indicating that leukotriene release from the endothelium might fine-tune myogenic tone. Because 5-lipoxygenase inhibition does not prevent release of eventually preformed leukotrienes, we next applied a neutralizing monoclonal antibody against leukotriene C 4 and D 4 , 14 which are the most potent CysLT 1 Rs agonists with EC 50 values of 11 and 1 nmol/L, respectively. The administration of neutralizing monoclonal antibody had no effect on myogenic tone. However, leukotriene E 4 , which is only a partial and weak agonist with markedly higher EC 50 value of 56 nmol/L, might still be effective. Therefore, total leukotriene C 4 , D 4 , and E 4 concentration in the bath solution superfusing the vessels during myogenic vasoconstriction was determined. Because leukotriene concentrations were below the detection limit of ≈100 pmol/L, these findings indicate that endogenously produced leukotrienes are not essential for myogenic vasoconstriction. In summary, our findings suggest a newly discovered role of CysLT 1 Rs as mechanosensors in the vasculature, where AT 1 and CysLT 1 receptors cooperate as mechanosensors mediating myogenic vasoconstriction via G q/11 -protein activation.
CysLT 1 Rs Are Mechanosensitive Independent of Endogenous Agonist
To confirm the ex vivo results on a cellular level, fluorimetric calcium measurements with fura-2-loaded mesenteric VSMCs of WT and AT 1A/1B −/− mice were performed. Interestingly, basal intracellular calcium concentrations [Ca 2+ ] i were significantly increased in AT 1A/1B −/− VSMCs (Figure 2A-2C ) most likely reflecting the hyper-reactivity of AT 1A/1B −/− arteries at low pressure levels, which was verified measuring basal [Ca 2+ ] i after incubation of 50 nmol/L pranlukast for 10 minutes. Indeed, basal [Ca 2+ ] i of AT 1A/1B −/− VSMCs were significantly reduced by pranlukast ( Figure 2C ). Hypo-osmotically induced [Ca 2+ ] i increases were similar in both cell types, and 50 nmol/L pranlukast significantly suppressed membrane stretch-induced [Ca 2+ ] i transients to a similar extent (Figure 2A-2C) . The combined application of pranlukast and candesartan suppressed [Ca 2+ ] i increases in WT VSMCs (Figure 2A and 2C) even more prominently.
To analyze whether mechanical CysLT 1 R activation is independent of endogenously produced leukotrienes, we incubated cells with the 5-lipoxygenase inhibitor zileuton for ≥30 minutes to prevent leukotriene production. In the presence of 100 µmol/L zileuton, VSMCs still responded to hypoosmotic membrane stretch with [Ca 2+ ] i increases that were not different from untreated cells ( Figure 2D and 2E ). To exclude an involvement of preformed leukotrienes in mechanically induced [Ca 2+ ] i increases, we incubated VSMCs with zileuton together with the neutralizing monoclonal antibody ( Figure 2D and 2E) resulting in unaltered mechanically induced [Ca 2+ ] i increases, suggesting that endogenously produced leukotrienes are not involved in mechanical VSMC activation.
Moreover, calcium imaging experiments were performed with human embryonic kidney 293 cells transiently overexpressing human CysLT 1 Rs. Untransfected human embryonic kidney 293 cells were unresponsive to hypo-osmotic membrane stretch and to pranlukast applications ( Figure 2F and  2G) . Hypo-osmotic cell swelling caused calcium transients in CysLT 1 Rs overexpressing cells that were significantly suppressed by pranlukast ( Figure 2F and 2G ). Because human embryonic kidney 293 cells do not produce leukotrienes, these findings suggest that stretch-induced CysLT 1 R activation was agonist independent, arguing in favor of intrinsic mechanosensitivity. Altogether, our findings provide evidence for a hitherto unknown function of CysLT 1 Rs as potential mechanosensors in resistance arteries involved in the regulation of vascular tone.
Discussion
AT 1A/1B −/− arteries exhibited an increased myogenic tone at low and a reduced myogenic tone at high intraluminal pressures. This is an uncovering novel vascular phenotype of AT 1A/1B −/− mice because until now, AT 1A/1B −/− mice have been known only for reduced blood pressure 15, 16 and reduced angiotensin II response 15 similar to AT 1A −/− mice. Moreover, growth, body weight, and survival rate were significantly reduced, and an abnormal kidney morphology was observed in AT 1A/1B −/− mice, 15 suggesting an essential role of AT 1 Rs in viability and health. Because AT 1A/1B −/− vessels did not exhibit a complete suppression of myogenic responsiveness, myogenic vasoconstriction seems to be of such pivotal importance for the regulation of blood flow that several distinct safety strategies may have evolved for compensation purposes. In the case of AT 1A/1B −/− mice, G q/11 -protein-coupled CysLT 1 Rs were upregulated as an essential backup strategy. However, CysLT 1 Rs could not completely compensate the loss of AT 1 Rs. Probably, they possess mechanosensory properties distinct from AT 1 Rs with a higher sensitivity for mechanical stimuli at low pressure ranges resulting in hyper-reactivity of AT 1A/1B −/− arteries. However, at high intraluminal pressure levels, myogenic tone was reduced reflecting the lack of AT 1 Rs.
The discovery of the novel role of CysLT 1 Rs in a genedeficient mouse model gave rise to the even more important and novel finding that CysLT 1 Rs possess an important biological function as mechanosensors mediating myogenic vasoconstriction even of WT arteries. Most strikingly, pranlukast and montelukast also reduced myogenic responsiveness of WT vessels revealing an uncovering novel function of CysLT 1 Rs as possible mechanosensors involved in myogenic vasoconstriction.
CysLT 1 Rs are known as constrictor receptors in smooth muscle. In particular, they play a dominant role for bronchoconstriction in the lung in asthma. 17, 18 However, an involvement in myogenic vasoconstriction and in particular a mechanosensitive function of CysLT 1 Rs has not been described before. Our findings with heterologously expressed CysLT 1 Rs clearly demonstrate that these receptors are mechanosensitive per se without the involvement of endogenous agonists. In the recombinant system, 50 nmol/L pranlukast significantly suppressed cell swelling-induced calcium transients. The mild effect of pranlukast on stretch-induced receptor activation might at least partially be caused by the lack of negative intrinsic activity of this compound. Moreover, the 5-lipoxygenase inhibitor zileuton administered to VSMCs to prevent endogenous leukotriene production and the additional application of a neutralizing leukotriene antibody had no effect, suggesting that leukotrienes are not involved in mechanical VSMC activation. However, in the isolated artery segment, zileuton slightly suppressed myogenic tone at high intraluminal pressures. This effect was endothelium mediated because de-endothelialized arteries showed normal myogenic tone indicating that endothelium-derived leukotrienes only fine-tune myogenic responsiveness. However, a neutralizing leukotriene antibody did not significantly reduce myogenic vasoconstriction, demonstrating that leukotrienes are not essentially involved in mechanical CysLT 1 Rs activation during myogenic vasoconstriction. Moreover, the lack of detectable leukotrienes in the bath solution superfusing pressurized arteries during myogenic vasoconstriction strongly argues for a leukotriene-independent CysLT 1 Rs activation.
Interestingly, simultaneous blockade of AT 1 and CysLT 1 receptors caused a similar reduction of myogenic tone as specific inhibition of the G q/11 -protein pathway, indicating that G-protein-coupled receptors determine ≈60% of myogenic vasoconstriction via G q/11 -proteins implying that 40% of myogenic tone is mediated by other mechanosensory elements.
Altogether our findings suggest an uncovering novel role of CysLT 1 Rs cooperating with AT 1 Rs as mechanosensors initiating myogenic vasoconstriction via the G q/11 -protein signaling pathway. Because myogenic vasoconstriction is of such vital interest and is found to be impaired in various pathological states, such as systemic hypertension, diabetes mellitus and stroke, our findings may help identify new and verify known pharmacological targets.
Myogenic vasoconstriction or Bayliss effect is essential for the maintenance of vascular tone, peripheral resistance, and organ perfusion. Therefore, a better understanding of mechanosensors mediating myogenic vasoconstriction may help identify new and evaluate known targets for the treatment of common diseases, such as stroke, hypertension, and diabetes mellitus, characterized by impaired myogenic vasoconstriction. In this study, we identified cysteinyl leukotriene 1 receptors as novel mechanosensors in the vasculature cooperating with angiotensin II type 1 receptors as mechanosensitive elements thereby determining >60% of myogenic tone via the G q/11 -protein signaling pathway.
Significance
